scispace - formally typeset
Search or ask a question
Journal ArticleDOI

'Vaping' profiles and preferences: an online survey of electronic cigarette users.

01 Jun 2013-Addiction (University of East London)-Vol. 108, Iss: 6, pp 1115-1125
TL;DR: E-cigarettes are used primarily for smoking cessation, but for a longer duration than nicotine replacement therapy, and users believe them to be safer than smoking.
Abstract: Aims to characterize e-cigarette use, users, and effects, in a sample of Electronic Cigarette Company (TECC) and Totally Wicked E-Liquid (TWEL) users. Design and Setting Online survey hosted at the University of East London with links from TECC/TWEL websites between September 2011 to May 2012. Measurements Online questionnaire. Participants 1347 respondents from 33 countries (72% European), mean age 43 years, 70% male, 96% Causacian, 44% educated to degree level or above. Findings 74% reported not smoking for at least a few weeks since using the e-cigarette and 70% reported reduced urge to smoke. 72% of participants used a ‘tank’ system, most commonly, the eGo-C (23%). Mean duration of use was 10 months. Only 1% reported exclusive use of non-nicotine (0mg) containing liquid. E-cigarettes were generally considered to: be satisfying to use; elicit few side effects; be healthier than smoking; improve cough/breathing; and be associated with low levels of craving. Among ex-smokers, ‘time to first vape’ was significantly longer than ‘time to first cigarette’(t1104=11.16, P <0.001) suggesting a lower level of dependence to e-cigarettes. Ex-smokers reported significantly greater reduction in craving than current smokers (χ21 =133.66, P<0.0007) although few other differences emerged between these groups. Compared to males, females opted more for chocolate/sweet flavours (χ21 =16.16, P< 0.001) and liked the e-cigarette because it resembles a cigarette(χ23 = 42.65, P< 0.001). Conclusions E-cigarettes tend to be used for smoking cessation but for a longer duration than NRT and were generally regarded as efficacious. Future research should focus on possible long-term health risks, abuse liability and cessation efficacy.

Summary (2 min read)

Introduction

  • Electronic cigarettes are battery-operated devices that deliver nicotine via inhaled vapour.
  • 'Smoking' an electronic cigarette (e-cigarette) mimics the act of smoking and is often referred to as 'vaping'.
  • Users can mix their own 'liquid' choosing from a range of flavours and strengths to refill cartridges.
  • This suggests the use of more sophisticated devices and/or experienced use is necessary for achieving effective nicotine delivery.
  • The first survey of e-cigarette users (N = 3587; 62% from US) has recently been published and has helped to answer some of these questions [11] .

Method

  • The questionnaire was hosted on the University of East London (UEL) website with links from TECC and TWEL websites.
  • D) Use of the e-cigarette, including length of use, product and cartridge type, strength and preferred flavours, amount used , reasons for use (e.g. as a complete or partial alternative to smoking.
  • Other comments based on general patterns of use (to be analysed and presented elsewhere).

Statistical analysis

  • Results are presented for the whole sample (including 4 never-smokers who reported using the e-cigarette) and then for smoking group: ex-smokers (N = 1123) vs. current smokers (N = 218) under each category heading.
  • Sample sizes vary by variable due to missing data.
  • T-tests are used to compare means for continuous variables and frequency data are analysed using cross-tabulation with chi-square statistics.
  • In some cases respondents could endorse more than one option (i.e. strength of liquid used, preferred flavour) whereas other variables were forced-choice (different response options indicated in tables).

Participant information

  • Of the total 1376 responses, 27 were removed: 13 were blank; 10 were double entries, and 4 had considerable missing data.
  • There were no significant differences between ex and current smokers on any demographic variable or country of origin.
  • Compared with current smokers, ex-smokers as a group reported a higher level of cigarette dependence (FTCD total, See Table 1 ) and reported smoking sooner after waking (FTCD, question 1) but age of starting smoking did not differ by group.
  • Thirty-eight percent of exsmokers reported that they had stopped smoking for more than one year; 19% had stopped for between 6 and 11 months and 43% for less than 6 months.

E-cigarette patterns of use

  • Duration of e-cigarette use was significantly longer in current than ex-smokers whilst exsmokers reported using the e-cigarette sooner after waking than did current smokers.
  • Table 2 also provides frequencies and percentages for strengths and flavours used.
  • There were no differences between current smokers and ex-smokers with respect to flavour preference.

E-cigarette reasons for use and effects on tobacco consumption

  • Survey respondents were asked why they started using the e-cigarette (see Table 3 ).
  • Seventy-six percent (1027) of the whole sample reported wanting a 'complete alternative to smoking'.
  • In the whole sample, 74% (n = 981) reported that they had not smoked for several weeks to several months since using the e-cigarette and a further 14% (n = 184) reported that their cigarette consumption had decreased dramatically.
  • Endorsement of this response was also significantly greater in ex than current smokers (see Table 3 ).

Positive effects of the e-cigarette

  • Table 4 presents the percentage of the whole sample, and breakdown by smoking group, endorsing the 'not at all' and the 'very much so' responses relating to e-cigarette effects.
  • Overall this sample reported positive effects of e-cigarette use, satisfaction levels were high and there was little evidence that e-cigarette use induced strong craving levels.
  • A significantly higher proportion of ex-smokers reported that e-cigarette use: had helped them to stop or cut down smoking; was extremely satisfying; had reduced tobacco craving/urge to smoke; improved their cough and breathing, and felt healthier than smoking (see Table 4 ).

Negative effects of the e-cigarette

  • Very few adverse effects of e-cigarette use were reported (see Table 5 ).
  • The most common was throat irritation, followed by mouth irritation.
  • Of all the other side effects listed, less than 16% (n < 202) reported experiencing any degree of effect and less than 3% (n < 32) reported a high level of side effects.
  • There were no significant differences with respect to reporting of adverse effects between ex-and current smokers.

Gender differences

  • Females, however, were just as likely as males to report using custom made devices.
  • Tabular data are not presented for gender; this is available on request.
  • There were no significant gender differences for any of the items relating to reasons for use, effects on tobacco consumption or craving, or attempt to cut down e-cigarette use.

Discussion

  • The present study aimed to characterize e-cigarette use, users, and effects, in a sample of visitors to TECC and TWEL websites.
  • Females opted more for chocolate/sweet flavours whereas males preferred tobacco flavoured liquids and tank systems.
  • Only 1% of the sample reported exclusive use of non-nicotine (0mg).
  • E-cigarettes were generally rated to be satisfying to use, associated with a dramatic reduction in tobacco craving and almost half of the sample agreed that the 'hit' was comparable to that of tobacco smoking.
  • Such respondents are likely to be current users with positive biases towards the e-cigarette, thus it is likely that unsatisfied users and ex-users are under-represented in this sample.

Did you find this useful? Give us your feedback

Content maybe subject to copyright    Report

1
‘Vaping’ profiles and preferences: an
online survey of electronic cigarette
users
Lynne Dawkins
1
, John Turner, Amanda Roberts and Kirstie Soar
School of Psychology
University of East London
Water Lane
Stratford
London E15 4LZ
1
Correponding author: tel.: 020 8223 4421
e-mail: l.e.dawkins@uel.ac.uk
Running Head: Vaping profiles and preferences
Word Count: 4,499
Declaration of Interest
No funding was received for this study. The first author has a collaborative
relationship with the Electronic Cigarette Company (TECC) and Totally Wicked
E-Liquids (TWEL). TECC and TWEL reviewed and approved the content of the
questionnaire and set up links from their web-sites to the host site at UEL.

2
Abstract
Aims to characterize e-cigarette use, users, and effects, in a sample of Electronic Cigarette
Company (TECC) and Totally Wicked E-Liquid (TWEL) users. Design and Setting Online
survey hosted at the University of East London with links from TECC/TWEL websites
between September 2011 to May 2012. Measurements Online questionnaire. Participants
1347 respondents from 33 countries (72% European), mean age 43 years, 70% male, 96%
Causacian, 44% educated to degree level or above. Findings 74% reported not smoking for
at least a few weeks since using the e-cigarette and 70% reported reduced urge to smoke.
72% of participants used a ‘tank’ system, most commonly, the eGo-C (23%). Mean duration
of use was 10 months. Only 1% reported exclusive use of non-nicotine (0mg) containing
liquid. E-cigarettes were generally considered to: be satisfying to use; elicit few side effects;
be healthier than smoking; improve cough/breathing; and be associated with low levels of
craving. Among ex-smokers, ‘time to first vape’ was significantly longer than ‘time to first
cigarette’ (t
1104
=11.16, P <0.001) suggesting a lower level of dependence to e-cigarettes. Ex-
smokers reported significantly greater reduction in craving than current smokers (χ
2
1
=133.66, P<0.0007) although few other differences emerged between these groups.
Compared to males, females opted more for chocolate/sweet flavours (χ
2
1
=16.16, P< 0.001)
and liked the e-cigarette because it resembles a cigarette(χ
2
3
= 42.65, P< 0.001). Conclusions
E-cigarettes tend to be used for smoking cessation but for a longer duration than NRT and
were generally regarded as efficacious. Future research should focus on possible long-term
health risks, abuse liability and cessation efficacy.

3
Introduction
Electronic cigarettes are battery-operated devices that deliver nicotine via inhaled vapour.
Removable cartridges contain glycerol or propylene glycol, flavouring, and varying amounts
of nicotine (including 0mg). The nicotine solution is vaporized by an atomizer which is
activated by 'drawing' on the device or pressing a button. 'Smoking' an electronic cigarette
(e-cigarette) mimics the act of smoking and is often referred to as 'vaping'.
Since their introduction into the market in 2004 by the Ruyan Group (later re-named
Dragonite) in China, e-cigarettes have gained popularity worldwide. The e-cigarette market
is rapidly growing and highly fragmented with over 100 different brands. Its estimated
revenue at retail in the US in May 2012 was over $250 million and is expected to double by
the end of 2012 [1,2].
Product sophistication has also improved during this time, arguably augmenting nicotine
delivery. 'Tank' systems have been introduced which contain a fluid-filled reservoir rather
than a saturated foam (traditional non-tank cartridges). Users can mix their own 'liquid'
choosing from a range of flavours and strengths to refill cartridges. Some e-cigarettes (e.g.
the Super & Mini kits from TECC) are moving to 'cartomizers' in which the cartridge and
atomizer are combined, allegedly resulting in a more efficient and tastier vape. Finally, since
different voltages affect the vaping experience, variable voltage are a recent power control
device that allow users to connect a range of atomizing devices and control the voltage that
is applied to the atomizer.
In a recent, online population survey of 2649 adults in the US [3] 40.2% of respondents had
heard of e-cigarettes and 11.4% of smokers, 2% of ex-smokers and 0.5% of never-smokers
had used them. In another survey of US individuals (n=222) who had purchased an e-
cigarette, 67% of respondents reported that they had reduced their cigarette consumption
and 49% had quit smoking completely (period of time unspecified) [4]. Nevertheless in the

4
absence of data supporting these cessation claims, the World Health Organization (WHO)
have banned therapeutic claims by manufacturers.
Although there is an absence of clinical trial data for e-cigarettes, three published empirical
studies suggest they can provide moderate relief of craving and withdrawal symptoms
[5,6,7]. Reports regarding delivery to the blood stream are inconsistent; three human
studies reported very low blood nicotine levels in naive users [5,6,8] whilst significant
increases in salivary cotinine (a nicotine metabolite) [9] and blood nicotine levels [10] have
been shown in regular users. This suggests the use of more sophisticated devices and/or
experienced use is necessary for achieving effective nicotine delivery.
More still needs to be determined about the nature of e-cigarette use, namely: who uses
them, their effectiveness for quitting/harm reduction, safety and addictive potential. The
first survey of e-cigarette users (N = 3587; 62% from US) has recently been published and
has helped to answer some of these questions [11]. Sixty-one percent of the sample were
men, 70% ex-smokers and 92% agreed that the e-cigarette had helped them to quit or
reduce their smoking. Most (84%) perceived the e-cigarette to be less toxic than smoking
and reported using it to deal with tobacco craving (79%) and withdrawal symptoms (67%) or
to quit smoking or avoid relapsing (77%).
This study aims to add to the current knowledge of the nature of e-cigarette users, its use,
and its effects. To ensure validity and generalizability, we used a more restricted sample of
The Electronic Cigarette Company (TECC) and Totally Wicked E-Liquid (TWEL) users (the two
most widely-used brands in the UK; [11]) recruited via their websites. We aimed to capture
information regarding: the characteristics of e-cigarette users (e.g. age, gender, educational
status and why they choose to use the e-cigarette); the nature of e-cigarette use (e.g. length
and frequency of use, amount used, preferred flavours and devices, possible dependency
and attempts to cut down); and positive (e.g. satisfaction, acceptability, effects on craving
and smoking-behaviour) and negative effects (e.g. nausea, dizziness, throat/mouth
irritation) of e-cigarette use.

5
Method
The questionnaire was hosted on the University of East London (UEL) website with links
from TECC and TWEL websites. Data were collected between September 2011 and May
2012. The survey was fully approved by the University of East London’s ethics committee.
The questionnaire took approximately 15-20 minutes to complete and comprised 6 sections
assessing:
A) Demographic information (age, gender, ethnicity, education and country) and smoking
status: current smoker, ex-smoker or never-smokers (fewer than 20 cigarettes in your
lifetime). Participants were directed to different sections depending on their smoking
status.
C) Tobacco Smoking Information, including the Fagerström Test of Cigarette Dependence
(FTCD; [12]), a six-item scale to assess cigarette dependence. Question 1 (commonly
considered the strongest single-item predictor of dependence) asks: 'how soon after
waking do you/did you smoke your first cigarette'? Participants indicate: 'within 5 minutes'
(scored 3), 'between 6-30 minutes' (scored 2), '31-60 minutes' (scored 1) or 'after 60
minutes' (scored 0). Total scores are calculated on the 6-items and scores range from 0
(low dependence) to 10 (high dependence). An adapted version with wording in the past
tense was used if participants indicated that they were ex-smokers. Ex-smokers were also
asked ‘how long has it been since you stopped smoking?’ (less than 6 months, 6 months to 1
year, more than one year, more than 2 years).
D) Use of the e-cigarette, including length of use, product and cartridge type, strength and
preferred flavours, amount used (in ml and puffs; where participants indicated a range, we
took the top figure and refer to ‘maximum daily use’), reasons for use (e.g. as a complete or
partial alternative to smoking. Note: we did not specifically ask about use for quitting
smoking as we did not want to prime respondents to endorse this response), dependence
on the e-cigarette and attempts to cut down use.
E) Effects of the e-cigarette including satisfaction, hit, acceptability, taste, urge to smoke,
impact on smoking behaviour and respiratory effects, all rated on a 4-point Likert Scale from
'not at all' to 'very much so'.

Citations
More filters
Journal ArticleDOI
TL;DR: E-cigarettes, with or without nicotine, were modestly effective at helping smokers to quit, with similar achievement of abstinence as with nicotine patches, and few adverse events.

986 citations

Journal ArticleDOI
TL;DR: The safety and effect of using ECs to help people who smoke achieve long-term smoking abstinence and the main outcome measure was abstinence from smoking after at least six months follow-up is evaluated.
Abstract: Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. BACKGROUND: Electronic cigarettes (ECs) are handheld electronic vaping devices which produce an aerosol formed by heating an e-liquid. People who smoke report using ECs to stop or reduce smoking, but some organisations, advocacy groups and policymakers have discouraged this, citing lack of evidence of efficacy and safety. People who smoke, healthcare providers and regulators want to know if ECs can help people quit and if they are safe to use for this purpose. This review is an update of a review first published in 2014. OBJECTIVES: To evaluate the effect and safety of using electronic cigarettes (ECs) to help people who smoke achieve long-term smoking abstinence. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group's Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO for relevant records to January 2020, together with reference-checking and contact with study authors. SELECTION CRITERIA: We included randomized controlled trials (RCTs) and randomized cross-over trials in which people who smoke were randomized to an EC or control condition. We also included uncontrolled intervention studies in which all participants received an EC intervention. To be included, studies had to report abstinence from cigarettes at six months or longer and/or data on adverse events (AEs) or other markers of safety at one week or longer. DATA COLLECTION AND ANALYSIS: We followed standard Cochrane methods for screening and data extraction. Our primary outcome measures were abstinence from smoking after at least six months follow-up, AEs, and serious adverse events (SAEs). Secondary outcomes included changes in carbon monoxide, blood pressure, heart rate, blood oxygen saturation, lung function, and levels of known carcinogens/toxicants. We used a fixed-effect Mantel-Haenszel model to calculate the risk ratio (RR) with a 95% confidence interval (CI) for dichotomous outcomes. For continuous outcomes, we calculated mean differences. Where appropriate, we pooled data from these studies in meta-analyses. MAIN RESULTS: We include 50 completed studies, representing 12,430 participants, of which 26 are RCTs. Thirty-five of the 50 included studies are new to this review update. Of the included studies, we rated four (all which contribute to our main comparisons) at low risk of bias overall, 37 at high risk overall (including the 24 non-randomized studies), and the remainder at unclear risk. There was moderate-certainty evidence, limited by imprecision, that quit rates were higher in people randomized to nicotine EC than in those randomized to nicotine replacement therapy (NRT) (risk ratio (RR) 1.69, 95% confidence interval (CI) 1.25 to 2.27; I2 = 0%; 3 studies, 1498 participants). In absolute terms, this might translate to an additional four successful quitters per 100 (95% CI 2 to 8). There was low-certainty evidence (limited by very serious imprecision) of no difference in the rate of adverse events (AEs) (RR 0.98, 95% CI 0.80 to 1.19; I2 = 0%; 2 studies, 485 participants). SAEs occurred rarely, with no evidence that their frequency differed between nicotine EC and NRT, but very serious imprecision led to low certainty in this finding (RR 1.37, 95% CI 0.77 to 2.41: I2 = n/a; 2 studies, 727 participants). There was moderate-certainty evidence, again limited by imprecision, that quit rates were higher in people randomized to nicotine EC than to non-nicotine EC (RR 1.71, 95% CI 1.00 to 2.92; I2 = 0%; 3 studies, 802 participants). In absolute terms, this might again lead to an additional four successful quitters per 100 (95% CI 0 to 12). These trials used EC with relatively low nicotine delivery. There was low-certainty evidence, limited by very serious imprecision, that there was no difference in the rate of AEs between these groups (RR 1.00, 95% CI 0.73 to 1.36; I2 = 0%; 2 studies, 346 participants). There was insufficient evidence to determine whether rates of SAEs differed between groups, due to very serious imprecision (RR 0.25, 95% CI 0.03 to 2.19; I2 = n/a; 4 studies, 494 participants). Compared to behavioural support only/no support, quit rates were higher for participants randomized to nicotine EC (RR 2.50, 95% CI 1.24 to 5.04; I2 = 0%; 4 studies, 2312 participants). In absolute terms this represents an increase of six per 100 (95% CI 1 to 14). However, this finding was very low-certainty, due to issues with imprecision and risk of bias. There was no evidence that the rate of SAEs varied, but some evidence that non-serious AEs were more common in people randomized to nicotine EC (AEs: RR 1.17, 95% CI 1.04 to 1.31; I2 = 28%; 3 studies, 516 participants; SAEs: RR 1.33, 95% CI 0.25 to 6.96; I2 = 17%; 5 studies, 842 participants). Data from non-randomized studies were consistent with RCT data. The most commonly reported AEs were throat/mouth irritation, headache, cough, and nausea, which tended to dissipate over time with continued use. Very few studies reported data on other outcomes or comparisons and hence evidence for these is limited, with confidence intervals often encompassing clinically significant harm and benefit. AUTHORS' CONCLUSIONS: There is moderate-certainty evidence that ECs with nicotine increase quit rates compared to ECs without nicotine and compared to NRT. Evidence comparing nicotine EC with usual care/no treatment also suggests benefit, but is less certain. More studies are needed to confirm the degree of effect, particularly when using modern EC products. Confidence intervals were wide for data on AEs, SAEs and other safety markers. Overall incidence of SAEs was low across all study arms. We did not detect any clear evidence of harm from nicotine EC, but longest follow-up was two years and the overall number of studies was small. The main limitation of the evidence base remains imprecision due to the small number of RCTs, often with low event rates. Further RCTs are underway. To ensure the review continues to provide up-to-date information for decision-makers, this review is now a living systematic review. We will run searches monthly from December 2020, with the review updated as relevant new evidence becomes available. Please refer to the Cochrane Database of Systematic Reviews for the review's current status.

731 citations

Journal ArticleDOI
TL;DR: E-cigarette use and cigarette smoking cessation among adult cigarette smokers, irrespective of their motivation for using e-cigarettes, are associated with significantly less quitting among smokers.

726 citations

Reference EntryDOI
TL;DR: The main outcome measure was abstinence from smoking after at least six months follow-up, and was the most rigorous definition available (continuous, biochemically validated, longest follow- up).
Abstract: © 2014 The Cochrane Collaboration. Background: Electronic cigarettes (ECs) are electronic devices that heat a liquid - usually comprising propylene glycol and glycerol, with or without nicotine and flavours, stored in disposable or refillable cartridges or a reservoir - into an aerosol for inhalation. Since ECs appeared on the market in 2006 there has been a steady growth in sales. Smokers report using ECs to reduce risks of smoking, but some healthcare organisations have been reluctant to encourage smokers to switch to ECs, citing lack of evidence of efficacy and safety. Smokers, healthcare providers and regulators are interested to know if these devices can reduce the harms associated with smoking. In particular, healthcare providers have an urgent need to know what advice they should give to smokers enquiring about ECs. Objectives: To examine the efficacy of ECs in helping people who smoke to achieve long-term abstinence; to examine the efficacy of ECs in helping people reduce cigarette consumption by at least 50% of baseline levels; and to assess the occurrence of adverse events associated with EC use. Search methods: We searched the Cochrane Tobacco Addiction Groups Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and two other databases for relevant records from 2004 to July 2014, together with reference checking and contact with study authors. Selection criteria: We included randomized controlled trials (RCTs) in which current smokers (motivated or unmotivated to quit) were randomized to EC or a control condition, and which measured abstinence rates or changes in cigarette consumption at six months or longer. As the field of EC research is new, we also included cohort follow-up studies with at least six months follow-up. We included randomized cross-over trials and cohort follow-up studies that included at least one week of EC use for assessment of adverse events. Data collection and analysis: One review author extracted data from the included studies and another checked them. Our main outcome measure was abstinence from smoking after at least six months follow-up, and we used the most rigorous definition available (continuous, biochemically validated, longest follow-up). For reduction we used a dichotomous approach (no change/reduction < 50% versus reduction by 50% or more of baseline cigarette consumption). We used a fixed-effect Mantel-Haenszel model to calculate the risk ratio (RR) with a 95% confidence interval (CI) for each study, and where appropriate we pooled data from these studies in meta-analyses. Main results: Our search identified almost 600 records, from which we include 29 representing 13 completed studies (two RCTs, 11 cohort). We identified nine ongoing trials. Two RCTs compared EC with placebo (non-nicotine) EC, with a combined sample size of 662 participants. One trial included minimal telephone support and one recruited smokers not intending to quit, and both used early EC models with low nicotine content. We judged the RCTs to be at low risk of bias, but under the GRADE system the overall quality of the evidence for our outcomes was rated 'low' or 'very low' because of imprecision due to the small number of trials. A 'low' grade means that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. A 'very low' grade means we are very uncertain about the estimate. Participants using an EC were more likely to have abstained from smoking for at least six months compared with participants using placebo EC (RR 2.29, 95% CI 1.05 to 4.96; placebo 4% versus EC 9%; 2 studies; GRADE: low). The one study that compared EC to nicotine patch found no significant difference in six-month abstinence rates, but the confidence intervals do not rule out a clinically important difference (RR 1.26, 95% CI: 0.68 to 2.34; GRADE: very low). A higher number of people were able to reduce cigarette consumption by at least half with ECs compared with placebo ECs (RR 1.31, 95% CI 1.02 to 1.68, 2 studies; placebo: 27% versus EC: 36%; GRADE: low) and compared with patch (RR 1.41, 95% CI 1.20 to 1.67, 1 study; patch: 44% versus EC: 61%; GRADE: very low). Unlike smoking cessation outcomes, reduction results were not biochemically verified. None of the RCTs or cohort studies reported any serious adverse events (SAEs) that were considered to be plausibly related to EC use. One RCT provided data on the proportion of participants experiencing any adverse events. Although the proportion of participants in the study arms experiencing adverse events was similar, the confidence intervals are wide (ECs vs placebo EC RR 0.97, 95% CI 0.71 to 1.34; ECs vs patch RR 0.99, 95% CI 0.81 to 1.22). The other RCT reported no statistically significant difference in the frequency of AEs at three- or 12-month follow-up between the EC and placebo EC groups, and showed that in all groups the frequency of AEs (with the exception of throat irritation) decreased significantly over time. Authors' conclusions: There is evidence from two trials that ECs help smokers to stop smoking long-term compared with placebo ECs. However, the small number of trials, low event rates and wide confidence intervals around the estimates mean that our confidence in the result is rated 'low' by GRADE standards. The lack of difference between the effect of ECs compared with nicotine patches found in one trial is uncertain for similar reasons. ECs appear to help smokers unable to stop smoking altogether to reduce their cigarette consumption when compared with placebo ECs and nicotine patches, but the above limitations also affect certainty in this finding. In addition, lack of biochemical assessment of the actual reduction in smoke intake further limits this evidence. No evidence emerged that short-term EC use is associated with health risk.

560 citations

Journal ArticleDOI
TL;DR: This systematic review appraises existing laboratory and clinical research on the potential risks from electronic cigarette use, compared with the well-established devastating effects of smoking tobacco cigarettes to indicate that electronic cigarettes are by far a less harmful alternative to smoking.
Abstract: Electronic cigarettes are a recent development in tobacco harm reduction. They are marketed as less harmful alternatives to smoking. Awareness and use of these devices has grown exponentially in recent years, with millions of people currently using them. This systematic review appraises existing laboratory and clinical research on the potential risks from electronic cigarette use, compared with the well-established devastating effects of smoking tobacco cigarettes. Currently available evidence indicates that electronic cigarettes are by far a less harmful alternative to smoking and significant health benefits are expected in smokers who switch from tobacco to electronic cigarettes. Research will help make electronic cigarettes more effective as smoking substitutes and will better define and further reduce residual risks from use to as low as possible, by establishing appropriate quality control and standards.

517 citations

References
More filters
Journal ArticleDOI
TL;DR: A renaming of the FTND to the Fagerstrom Test for Cigarette Dependence (FTCD) is proposed, in light of what is now known about what determines cigarette smoking, it seems timely to propose a renaming.
Abstract: When the first version (the Tolerance Questionnaire, Fagerstrom, 1978) of the Fagerstrom Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) was developed, tobacco smoking was not regarded as an addiction. Nevertheless, evidence that this might be the case was beginning to appear, and some researchers became increasingly interested in investigating the importance of nicotine in the smoking habit and educating the public about it. The research led to a profound change in the understanding of cigarette smoking, and in 1988, the U.S. Surgeon General, in the remarkable book Nicotine Addiction, established once and “forever” the importance of nicotine in tobacco smoking (U.S. Department of Health and Human Services [U.S. DHHS], 1988). However, as the role of nicotine was established, researchers lost sight of the possibility that other determinants might also be important. More recently, it has been found that, although nicotine is the most important addictive component of tobacco smoke, it is probably not the only substance involved in the development of tobacco dependence. In light of what is now known about what determines cigarette smoking, it seems timely to propose a renaming of the FTND to the Fagerstrom Test for Cigarette Dependence (FTCD). The background for this is discussed in this commentary.

769 citations


"'Vaping' profiles and preferences: ..." refers methods in this paper

  • ...C) Tobacco Smoking Information, including the Fagerström Test of Cigarette Dependence (FTCD; [12]), a six-item scale to assess cigarette dependence....

    [...]

Journal ArticleDOI
TL;DR: E-cigarettes were used much as people would use nicotine replacement medications: by former smokers to avoid relapse or as an aid to cut down or quit smoking, and for quitting and relapse prevention.
Abstract: Aims To assess the profile, utilization patterns, satisfaction and perceived effects among users of electronic cigarettes (‘e-cigarettes’). Design and Setting Internet survey in English and French in 2010. Measurements Online questionnaire. Participants Visitors of websites and online discussion forums dedicated to e-cigarettes and to smoking cessation. Findings There were 3587 participants (70% former tobacco smokers, 61% men, mean age 41 years). The median duration of electronic cigarette use was 3 months, users drew 120 puffs/day and used five refills/day. Almost all (97%) used e-cigarettes containing nicotine. Daily users spent $33 per month on these products. Most (96%) said the e-cigarette helped them to quit smoking or reduce their smoking (92%). Reasons for using the e-cigaretteincludedtheperceptionthatitwaslesstoxicthantobacco(84%),todealwithcravingfortobacco(79%)and withdrawal symptoms (67%), to quit smoking or avoid relapsing (77%), because it was cheaper than smoking (57%) and to deal with situations where smoking was prohibited (39%). Most ex-smokers (79%) feared they might relapse to smoking if they stopped using the e-cigarette. Users of nicotine-containing e-cigarettes reported better relief of withdrawalandagreatereffectonsmokingcessationthanthoseusingnon-nicotinee-cigarettes.Conclusions E-cigarettes were used much as people would use nicotine replacement medications: by former smokers to avoid relapse or as an aid tocutdownorquitsmoking.Furtherresearchshouldevaluatethesafetyandefficacyof e-cigarettesforadministration of nicotine and other substances, and for quitting and relapse prevention.

668 citations


"'Vaping' profiles and preferences: ..." refers background or methods or result in this paper

  • ...This is particularly relevant to the current survey which was accessed by users of two leading UK e-cigarette retailer’s websites whereas participants in the previous survey [11] were sampled from e-cigarette discussion forums and more ‘neutral’ stop-smoking sites....

    [...]

  • ...The first survey of e-cigarette users (N = 3587; 62% from US) has recently been published and has helped to answer some of these questions [11]....

    [...]

  • ...To ensure validity and generalizability, we used a more restricted sample of The Electronic Cigarette Company (TECC) and Totally Wicked E-Liquid (TWEL) users (the two most widely-used brands in the UK; [11]) recruited via their websites....

    [...]

  • ...Given that there is also increasing evidence that reinforcing aspects of smoking/nicotine may differ by gender [7,13] and that vaping is more common among males [11], we also compared males (N = 897) vs....

    [...]

  • ...36ml of fluid and 236 puffs; higher figures than reported previously [11]....

    [...]

Journal ArticleDOI
TL;DR: The 16 mg Ruyan V8 ENDD alleviated desire to smoke after overnight abstinence, was well tolerated and had a pharmacokinetic profile more like the Nicorette inhalator than a tobacco cigarette.
Abstract: Objectives To measure the short-term effects of an electronic nicotine delivery device (“e cigarette”, ENDD) on desire to smoke, withdrawal symptoms, acceptability, pharmacokinetic properties and adverse effects. Design Single blind randomised repeated measures cross-over trial of the Ruyan V8 ENDD. Setting University research centre in Auckland, New Zealand. Participants 40 adult dependent smokers of 10 or more cigarettes per day. Interventions Participants were randomised to use ENDDs containing 16 mg nicotine or 0 mg capsules, Nicorette nicotine inhalator or their usual cigarette on each of four study days 3 days apart, with overnight smoking abstinence before use of each product. Main outcome measures The primary outcome was change in desire to smoke, measured as “area under the curve” on an 11-point visual analogue scale before and at intervals over 1 h of use. Secondary outcomes included withdrawal symptoms, acceptability and adverse events. In nine participants, serum nicotine levels were also measured. Results Over 60 min, participants using 16 mg ENDD recorded 0.82 units less desire to smoke than the placebo ENDD (p=0.006). No difference in desire to smoke was found between 16 mg ENDD and inhalator. ENDDs were more pleasant to use than inhalator (p=0.016) and produced less irritation of mouth and throat (p Conclusions The 16 mg Ruyan V8 ENDD alleviated desire to smoke after overnight abstinence, was well tolerated and had a pharmacokinetic profile more like the Nicorette inhalator than a tobacco cigarette. Evaluation of the ENDD for longer-term safety, potential for long-term use and efficacy as a cessation aid is needed. Trial registration No.12607000587404, Australia and New Zealand Clinical Trials Register

513 citations


"'Vaping' profiles and preferences: ..." refers background in this paper

  • ...Although there is an absence of clinical trial data for e-cigarettes, three published empirical studies suggest they can provide moderate relief of craving and withdrawal symptoms [5,6,7]....

    [...]

  • ...Reports regarding delivery to the blood stream are inconsistent; three human studies reported very low blood nicotine levels in naive users [5,6,8] whilst significant increases in salivary cotinine (a nicotine metabolite) [9] and blood nicotine levels [10] have been shown in regular users....

    [...]

Journal ArticleDOI
TL;DR: In both surveys, non-Hispanic Whites, current smokers, young adults, and those with at least a high-school diploma were most likely to perceive e-cigarettes as less harmful than regular cigarettes.
Abstract: Objectives. We estimated e-cigarette (electronic nicotine delivery system) awareness, use, and harm perceptions among US adults.Methods. We drew data from 2 surveys conducted in 2010: a national online study (n = 2649) and the Legacy Longitudinal Smoker Cohort (n = 3658). We used multivariable models to examine e-cigarette awareness, use, and harm perceptions.Results. In the online survey, 40.2% (95% confidence interval [CI] = 37.3, 43.1) had heard of e-cigarettes, with awareness highest among current smokers. Utilization was higher among current smokers (11.4%; 95% CI = 9.3, 14.0) than in the total population (3.4%; 95% CI = 2.6, 4.2), with 2.0% (95% CI = 1.0, 3.8) of former smokers and 0.8% (95% CI = 0.35, 1.7) of never-smokers ever using e-cigarettes. In both surveys, non-Hispanic Whites, current smokers, young adults, and those with at least a high-school diploma were most likely to perceive e-cigarettes as less harmful than regular cigarettes.Conclusions. Awareness of e-cigarettes is high, and use am...

499 citations


"'Vaping' profiles and preferences: ..." refers background in this paper

  • ...In a recent, online population survey of 2649 adults in the US [3] 40....

    [...]

Journal ArticleDOI
TL;DR: Evidence is accumulating to suggest that males and females may differ in factors that maintain tobacco smoking or nicotine self-administration, and identification of specific factors responsible for these sex differences may lead to improved interventions for smoking cessation and other substance abuse in women.
Abstract: Although both the human and animal literatures are notable for the general lack of attention paid to possible sex differences in drug self-administration behavior, evidence is accumulating to suggest that males and females may differ in factors that maintain tobacco smoking or nicotine self-administration. Self-administration of nicotine per se may be less robust in women, and women are less sensitive than men to some effects of nicotine that may be reinforcing. Compared to men, smoking behavior of women may be influenced more by non-nicotine stimuli associated with smoking, suggesting greater conditioned reinforcement of smoking in women. Moreover, nicotine replacement, the current standard treatment for smoking cessation, is sometimes less effective in women, further suggesting the need for greater consideration of non-nicotine factors that may maintain women's smoking. Very recent research on rats also indicates sex differences in nicotine self-administration. However, these differences are complex and suggest that nicotine-seeking behavior is composed of several components, including hedonic, incentive-motivational, and conditioning effects; males and females may differ in one or more of these components. Menstrual or estrous cycle phase effects on the maintenance of nicotine self-administration are not particularly apparent in humans or animals, although cycle phase may influence other stages of dependence (e.g., withdrawal symptoms during cessation). Future research should evaluate further the consistency of results across human and non-human species, identify the conditions and procedures under which sex differences are observed, and elucidate the specific components of reinforcement that may differ between males and females. Studies also should examine the possible generalizability of these sex differences to other drugs of abuse. Identification of specific factors responsible for these sex differences may lead to improved interventions for smoking cessation and other substance abuse in women.

397 citations


"'Vaping' profiles and preferences: ..." refers result in this paper

  • ...Given that there is also increasing evidence that reinforcing aspects of smoking/nicotine may differ by gender [7,13] and that vaping is more common among males [11], we also compared males (N = 897) vs....

    [...]

  • ...These observations resonate with the findings that, relative to males, females are less sensitive to the interoceptive effects of nicotine [16] and more responsive to nonnicotine, sensorimotor aspects of smoking [7,13,17]....

    [...]